Gatifloxacin + Prednisolone AcetateThird Party Manufacturing in India

Gatifloxacin + Prednisolone Acetate works by combining a broad-spectrum fluoroquinolone antibiotic with a potent synthetic corticosteroid to treat ocular infections accompanied by inflammation. Gatifloxacin operates as a bactericidal agent by targeting and inhibiting two bacterial enzymes: DNA gyrase (Topoisomerase II), which introduces negative supercoils into DNA for replication and transcription, and Topoisomerase IV, which separates replicated chromosomal DNA during cell division. By blocking these enzymes, it halts bacterial replication and repair, causing cell death. Concurrently, Prednisolone Acetate acts as a glucocorticoid receptor agonist. Upon binding, it modulates gene transcription, suppressing the synthesis of inflammatory mediators like prostaglandins and leukotrienes. This action reduces capillary permeability, leukocyte migration, and localized swelling, redness, and itching. Together, this combination eradicates the underlying bacterial infection while rapidly controlling the associated inflammatory response, preventing potential ocular tissue damage. It is highly effective for post-surgical recovery and severe bacterial conjunctivitis.

Therapeutic Uses

Gatifloxacin + Prednisolone Acetate ophthalmic suspension is indicated for:

• Steroid-Responsive Inflammatory Ocular Conditions: Treatment of ocular inflammation where bacterial infection or a risk of infection exists.
• Postoperative Inflammation and Infection: Managing pain, swelling, and preventing bacterial infection following cataract or refractive surgery.
• Bacterial Conjunctivitis & Blepharitis: Relieving symptoms of bacterial conjunctivitis and lid inflammation accompanied by significant swelling and discomfort.

Why Manufacturers Choose Gatifloxacin + Prednisolone Acetate

Gatifloxacin + Prednisolone Acetate is a highly popular ophthalmic combination in the pharmaceutical market. The combination of a fourth-generation fluoroquinolone and a corticosteroid offers dual-action relief, making it a preferred choice for ophthalmologists post-surgery. Its broad spectrum of activity against Gram-positive and Gram-negative ocular pathogens, combined with rapid anti-inflammatory action, ensures high patient compliance and excellent clinical outcomes.

For third party manufacturing in India, this combination represents a high-demand sterile formulation. Ophthalmic manufacturing utilizes state-of-the-art Blow-Fill-Seal (BFS) technology in WHO-GMP certified facilities, ensuring sterile and stable formulations. Celesta Healthcare offers customized packaging options and documentation support for domestic PCD franchise networks and international exports, making it a highly profitable addition to any ophthalmic product portfolio.